Business
Jenscare released its multi-product portfolio's, including LuX-Valve Plus TRINITY study, JensClip and Ken-Valve, remarkable clinical outcomes at TCT 2025 in the U.S.
Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company, recently released 6-month follow-up results of TRINITY Trial of LuX-Valve Plus, a promising self-developed TTVR system, and 1-year outcomes and challenging cases of JensClip and Ken-Valve, a proprietary TMVr system and TAVR (AR) system respectively, representing the Company's diversified and high-potential multi-product portfolio, at TCT 2025 in the U.S..
About this update from Jenscare Scientific Co. Ltd. Class H
[{"type":"text","content":"BEIJING, Oct. 29, 2025 /PRNewswire/ -- Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company, recently released 6-month follow-up results of TRINITY Trial of LuX-Valve Plus, a promising self-developed TTVR system, and 1-year outcomes and challenging cases of JensClip and Ken-Valve, a proprietary TMVr system and TAVR (AR) system respectively, representing the Company's diversified and high-potential multi-product portfolio, at TCT 2025 in the U.S..","length":532,"tagName":"p"},{"type":"text","content":"6-Month Follow-up Results of LuX-Valve Plus TRINITY Study -Released by Prof. Thomas Modine, CHU de Bordeaux-Haut-Leveque, France","length":129,"tagName":"p"},{"type":"text","content":"TRINITY is a global prospective, multicenter, single-arm clinical trial, which primarily aims to evaluate the safety and efficacy of LuX-Valve Plus in application on patients with severe tricuspid regurgitation and high surgical risk. The study enrolled 161 patients from 20 centers around the world, among which, 18 centers were from France, Germany, Spain, Denmark, and the UK.","length":379,"tagName":"p"},{"type":"text","content":"The average age of the patients (FAS + Roll-in group) is about 77 years old with an average STS score of 10.24%. 91.93% of the patients has atrial fibrillation, 32.92% has left heart surgery/intervention, 26.71% has pacemaker/ICD implanted. Patients are combined with multi other comorbidities, which formed a poor baseline and increased the risks of surgical treatment or difficulties of other interventional therapies. Over 75% of enrollments utilized valve sizes between 55mm and 70mm. The results show that the device success rate is about 97%, and the average device operation time is around 41.60 minutes with the shortest time being 11 minutes.","length":651,"tagName":"p"},{"type":"text","content":"The safety indicators show that the overall CEC-adjudicated composite events rate at 6-month of FAS + Roll-in group is 19.9%. Cardiovascular mortality is 3.7%, the incidence of strokes is 0.6%, new onset renal failure is 1.2%, non-selective tricuspid valve surgery/intervention post procedure is 2.5%, major cardiac structural complications is 3.1%, severe bleeding (including fatal, life-threatening and extensive bleeding as defined by MVARC) is 5.0%, ne...